Background. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main bacterial pathogens causing chronic infections, mainly because of its capacity to produce biofilm. Biofilm production is one of the underlying strategies for antibacterial drug resistance. Accordingly, preventing and attenuating biofilm production has become an emerging approach to controlling persistent infections. Therefore, this scoping review is aimed at surveying the published literature describing the usage of probiotics and their derivatives against biofilm-producing MRSA. Methods. Updated literature searches were conducted across seven electronic databases including Web of Science, PubMed, Scopus, Cochrane Library, ProQuest, Embase, and Google Scholar to identify all original published articles about probiotics against MRSA. In this regard, studies were summarized and analyzed in the present review. Results. In the reviewed studies, various microorganisms and compounds were used as probiotics as follows: Lactobacillus species (8 studies), Enterococcus species (4 studies), Bacillus species (2 studies), Streptomyces species (2 studies), Saccharomyces cerevisiae (1 study), Corynebacterium accolens (1 study), and Lactococcus lactis derived Nisin (3 studies). Based on our comprehensive search, 21 studies with eligibility criteria were included in the present review including 12 studies on clinical strains, 6 studies on ATCC, 2 studies simultaneously on clinical and standard strains, and finally 1 study on food sample. Conclusions. Our study showed that there was an increasing trend in the number of publications reporting probiotics against biofilm-producing MRSA. The results of this scoping review could use to guide the undertaking of the subsequent systematic reviews. In summary, probiotics with antimicrobial and antibiofilm properties can use as an embedded agent in food products or as a biopharmaceutical in the prevention and treatment of MRSA infections.

Backgrounds: Group B Streptococcus (GBS) is an important opportunistic bacterial pathogen that could cause serious infections, especially in neonates, adults, and the elderly. In GBS isolates, a macrolide resistance phenotype that confers constitutive resistance to macrolidelincosamide-streptogramin B antibiotics (cMLSB phenotype) has become a global concern. On the other hand, little is known about the genetic relatedness and diversity of GBS isolates isolated from various patients in Iran. Hence, this study aimed to determine the genetic relatedness and molecular typing of cMLSB-GBS isolates using enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) technique. Materials & Methods: A total of 100 GBS isolates were collected from patients with urinary tract infections (UTIs). Among them, 52 erythromycin-resistant GBS isolates were selected, and double-disc diffusion (D-zone) technique was applied to determine the MLSB phenotype among the isolates based on CLSI criteria. Then the genetic relatedness of MLSB-GBS isolates was assessed using ERIC-PCR fingerprinting method. Findings: Among 52 erythromycin-resistant GBS isolates, 38 isolates were identified with cMLSB phenotype, nine isolates with M phenotype, and five isolates with iMLSB phenotype. The analysis of ERIC-PCR patterns revealed eight different ERIC types that were divided into seven clusters (A-G) and one single type. Also, four isolates were non-typeable. ERIC type A/ serotype Ib was the most prevalent clone among the isolates. Conclusion:The current study findings showed a high level of diversity and multiclonal spread of the cMLSB phenotype in Isfahan. ERIC type A/ serotype Ib is the predominant clone circulating among erythromycin-resistant GBS strains.